Scientists have long known that restricting calories can fend off physiological signs of aging, with studies in fruit flies, roundworms, rodents and even people showing that chronically slashing intake by about a third can reap myriad health benefits and, in some cases, extend lifespan.
From a public health perspective, that advice would be impractical for many and dangerous for some.
But a new CU Boulder study published today indicates that when people consume a natural dietary supplement called nicotinomide riboside (NR) daily, it mimics caloric restriction, aka “CR,” kick-starting the same key chemical pathways responsible for its health benefits.
Supplementation also tends to improve blood pressure and arterial health, particularly in those with mild hypertension, the study found.
“This was the first ever study to give this novel compound to humans over a period of time,” said senior author Doug Seals, a professor and researcher in the Department of Integrative Physiology. “We found that it is well tolerated and appears to activate some of the same key biological pathways that calorie restriction does.”
For the study, published in the journal Nature Communications, Seals and lead author Chris Martens, then a postdoctoral fellow at CU Boulder, included 24 lean and healthy men and women ages 55 to 79 from the Boulder area.
Half were given a placebo for six weeks, then took a 500 mg twice-daily dose of nicotinamide riboside (NR) chloride (NIAGEN). The other half took NR for the first six weeks, followed by placebo.
The researchers took blood samples and other physiological measurements at the end of each treatment period.
Participants reported no serious adverse effects.
The researchers found that 1,000 mg daily of NR boosted levels of another compound called nicotinamide adenine dinucleotide (NAD+) by 60 percent. NAD+ is required for activation of enzymes called sirtuins, which are largely credited with the beneficial effects of calorie restriction. It’s involved in a host of metabolic actions throughout the body, but it tends to decline with age.
Research suggests that as an evolutionary survival mechanism, the body conserves NAD+ when subjected to calorie restriction. But only recently have scientists begun to explore the idea of supplementing with so-called “NAD+-precursors” like NR to promote healthy aging.
The Latest on: Nicotinomide riboside
via Google News
The Latest on: Nicotinomide riboside
- Why is ChromaDex Corporation (CDXC) up 17.20% from the day 1 this year?on October 19, 2021 at 10:03 am
For the readers interested in the stock health of ChromaDex Corporation (CDXC). It is currently valued at $5.86. When the transactions were called off in the previous session, Stock hit the highs of ...
- ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia ...on October 18, 2021 at 7:34 am
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movem ...
- ChromaDex Shares Findings from First Clinical...on October 18, 2021 at 3:55 am
The study investigated ChromaDex's proprietary Niagen ® ingredient (patented nicotinamide riboside, or "NR") in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative ...
- Global Nicotinamide Riboside(NR) Market 2021 Comprehensive Research Methodology, Key Insights, Segments and Extensive Profiles by 2027on October 11, 2021 at 2:40 pm
An empirical report titled Global Nicotinamide Riboside (NR) Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2027 is released by MarketsandResearch.biz with top quality and ...
- Tru Niagen Reviews: Does It Work? What to Know Before Buy!on October 8, 2021 at 6:32 am
Tru Niagen contains a patented ingredient called Niagen®, which stands for nicotinamide riboside chloride. Niagen helps act as a precursor to NAD, which belongs to the family of vitamin B3 and is ...
- ChromaDex Corporation (CDXC)on September 30, 2021 at 5:01 pm
The study investigated ChromaDex’s proprietary Niagen® ingredient (patented nicotinamide riboside, or "NR") in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder ...
- 'Get Rid of the Scumbags': Trade Secrets Battle Between ChromaDex, Elysium Offers Rare Look Inside Major Life Science Companieson September 29, 2021 at 10:00 pm
The trial that began Tuesday involves nicotinamide riboside, a key chemical in anti-aging supplements. Evidence includes personal text messages accidentally released by Elysium's now-former lawyers.
- ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)on September 20, 2021 at 3:35 am
New preclinical data from the ChromaDex External Research Program (CERP) shows positive effects of nicotinamide riboside (NR) in glaucoma, Alzheimer’s disease, and cardiac ischemia-reperfusion injury ...
via Bing News